Investigating the role of STARD3 in colorectal cancer
Official title: The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study: a Monocentric Observational Study
Run by Centro di Riferimento Oncologico - Aviano · NCT06136949 · Data updated 2026-11-12
This study is testing if a protein called STARD3 is linked to colorectal cancer and if it can help doctors understand how the cancer grows and responds to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 1 site (Aviano, Pordenone) |
| Status | Recruiting |
| Started | May 22, 2023 |
| Main results expected | December 31, 2032 |
| Study ends | December 31, 2032 |
| Registry record updated | November 18, 2023 |
| Trial ID | NCT06136949 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a histologically confirmed diagnosis of colorectal cancer, regardless of the stage.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or have a history of other malignancies within the past five years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on colorectal cancer (CRC) patients to verify the overexpression of STARD3 in tumor tissues, both in early and advanced stages. It aims to identify the pathways involved in tumorigenesis and cancer progression related to STARD3, while also exploring its potential as a dynamic biomarker for treatment response. The study utilizes patient-derived organoids to assess drug sensitivity and treatment efficacy in a controlled ex-vivo environment. By analyzing these organoids, researchers hope to gain insights into the therapeutic implications of STARD3 in CRC.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for colorectal cancer patients.
How similar studies have gone: While the specific approach of using STARD3 as a theranostic target is novel, similar studies utilizing organoids for drug sensitivity testing have shown promise in cancer research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage. * Age ≥18 years. * Signed informed consent form. * Availability of tissue and blood samples stored at the Institutional Biobank for research purposes. Exclusion Criteria: * Patients for which the tumour biobanking process could compromise the diagnostic assessments. * Pregnancy or breast-feeding. * History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
Where it's running
-
Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
Aviano, Pordenone, Italy Recruiting
Study contacts
- Principal investigator: Vincenzo Canzonieri, MD,PhD — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Vincenzo Canzonieri, MD, PhD
- Email: vcanzonieri@cro.it
- Phone: 0434 659 618
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.